Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ixekizumab treatment of biologic-naïve patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1).
Chandran V, van der Heijde D, Fleischmann RM, Lespessailles E, Helliwell PS, Kameda H, Burgos-Vargas R, Erickson JS, Rathmann SS, Sprabery AT, Birt JA, Shuler CL, Gallo G. Chandran V, et al. Among authors: lespessailles e. Rheumatology (Oxford). 2020 Oct 1;59(10):2774-2784. doi: 10.1093/rheumatology/kez684. Rheumatology (Oxford). 2020. PMID: 32031665 Free PMC article. Clinical Trial.
Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors.
Deodhar A, Poddubnyy D, Pacheco-Tena C, Salvarani C, Lespessailles E, Rahman P, Järvinen P, Sanchez-Burson J, Gaffney K, Lee EB, Krishnan E, Santisteban S, Li X, Zhao F, Carlier H, Reveille JD; COAST-W Study Group. Deodhar A, et al. Among authors: lespessailles e. Arthritis Rheumatol. 2019 Apr;71(4):599-611. doi: 10.1002/art.40753. Epub 2019 Mar 8. Arthritis Rheumatol. 2019. PMID: 30343531 Free PMC article. Clinical Trial.
Ixekizumab in the treatment of psoriatic arthritis.
Lespessailles E, Toumi H. Lespessailles E, et al. Immunotherapy. 2021 Jan;13(1):19-33. doi: 10.2217/imt-2020-0225. Epub 2020 Nov 9. Immunotherapy. 2021. PMID: 33167745 Review.
Continuation of treatment with infliximab in ankylosing spondylitis: 2-yr open follow-up.
Gossec L, Le Henanff A, Breban M, Vignon E, Claudepierre P, Devauchelle V, Wendling D, Lespessailles E, Euller-Ziegler L, Sibilia J, Perdriger A, Alexandre C, Dougados M. Gossec L, et al. Among authors: lespessailles e. Rheumatology (Oxford). 2006 Jul;45(7):859-62. doi: 10.1093/rheumatology/kel015. Epub 2006 Jan 25. Rheumatology (Oxford). 2006. PMID: 16436489 Clinical Trial.
Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.
Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, Lespessailles E, Hall S, Hochfeld M, Hu C, Hough D, Stevens RM, Schett G. Kavanaugh A, et al. Among authors: lespessailles e. Ann Rheum Dis. 2014 Jun;73(6):1020-6. doi: 10.1136/annrheumdis-2013-205056. Epub 2014 Mar 4. Ann Rheum Dis. 2014. PMID: 24595547 Free PMC article. Clinical Trial.
Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study.
Kiltz U, Sfikakis PP, Gaffney K, Sator PG, von Kiedrowski R, Bounas A, Gullick N, Conrad C, Rigopoulos D, Lespessailles E, Romanelli M, Ghislain PD, Brandt-Jürgens J, Rashkov R, Aassi M, Orsenigo R, Perella C, Pournara E, Gathmann S, Jagiello P, Veit J, Augustin M. Kiltz U, et al. Among authors: lespessailles e. Adv Ther. 2020 Jun;37(6):2865-2883. doi: 10.1007/s12325-020-01352-8. Epub 2020 May 6. Adv Ther. 2020. PMID: 32378070 Free PMC article.
177 results